WGS
The table below shows GeneDx Holdings Corp.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $102.25M | $116.74M | $102.69M | $87.11M | $76.87M | $70.51M |
| Cost of revenue | $34.04M | $32.22M | $31.79M | $28.64M | $29.05M | $27.56M |
| Gross profit | $68.21M | $84.53M | $70.90M | $58.48M | $47.83M | $42.95M |
| R&D | $19.80M | $19.83M | $15.08M | $12.58M | $11.66M | $10.90M |
GeneDx Holdings Corp. reported annual revenue of $427.54M for fiscal year 2025. That is up 40.0% from $305.45M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $196.17M (FY 2019) to $427.54M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $74.59M | $44.44M | $27.41M | $50.45M | $26.92M | $26.04M |
| Operating income | -$57.47M | -$3.25M | $8.96M | -$4.55M | -$7.78M | -$10.58M |
| Income tax | $897.00K | $247.00K | -$246.00K | $447.00K | -$47.00K | -$190.00K |
| Net income | -$63.32M | -$7.63M | $10.81M | -$6.53M | -$8.31M | -$29.17M |
| EPS (diluted) | -$2.16 | -$0.27 | $0.36 | -$0.23 | -$0.31 | -$1.10 |